Research Analysts Set Expectations for ALNY FY2024 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at Zacks Research boosted their FY2024 earnings per share estimates for shares of Alnylam Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of ($2.52) for the year, up from their prior estimate of ($2.65). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.21) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($1.00) EPS, Q1 2025 earnings at ($0.95) EPS, Q2 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($3.26) EPS, Q1 2026 earnings at $0.33 EPS, Q2 2026 earnings at $0.09 EPS, Q3 2026 earnings at $0.64 EPS and FY2026 earnings at $1.71 EPS.

Other research analysts have also recently issued reports about the stock. Piper Sandler reissued an “overweight” rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. Raymond James upped their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Finally, Barclays raised their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Stock Up 2.5 %

ALNY stock opened at $250.98 on Monday. The stock has a market capitalization of $32.37 billion, a PE ratio of -95.79 and a beta of 0.39. The company has a fifty day moving average of $273.13 and a 200-day moving average of $238.67. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same period in the previous year, the company posted $1.15 earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% on a year-over-year basis.

Institutional Trading of Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Acadian Asset Management LLC lifted its holdings in Alnylam Pharmaceuticals by 30.3% in the 1st quarter. Acadian Asset Management LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 386 shares in the last quarter. O Shaughnessy Asset Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 9.6% during the first quarter. O Shaughnessy Asset Management LLC now owns 2,181 shares of the biopharmaceutical company’s stock worth $326,000 after buying an additional 191 shares in the last quarter. UniSuper Management Pty Ltd raised its position in shares of Alnylam Pharmaceuticals by 100.0% in the first quarter. UniSuper Management Pty Ltd now owns 1,800 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 900 shares during the last quarter. Natixis purchased a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $102,000. Finally, Advisors Asset Management Inc. boosted its position in Alnylam Pharmaceuticals by 194.0% during the first quarter. Advisors Asset Management Inc. now owns 4,037 shares of the biopharmaceutical company’s stock worth $603,000 after acquiring an additional 2,664 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.